Ticker >

Natco Pharma share price

Natco Pharma Ltd.

NSE: NATCOPHARM BSE: 524816 SECTOR: Pharmaceuticals & Drugs  81k   375   74

991.20
+8.30 (0.84%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1004.65

Today's Low

₹ 973.55

52 Week High

₹ 1107.85

52 Week Low

₹ 520.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17753.37 Cr.

Enterprise Value

17501.27 Cr.

No. of Shares

17.91 Cr.

P/E

14.65

P/B

3.36

Face Value

₹ 2

Div. Yield

0.55 %

Book Value (TTM)

₹  295.19

CASH

412 Cr.

DEBT

159.9 Cr.

Promoter Holding

49.71 %

EPS (TTM)

₹  67.65

Sales Growth

32.99%

ROE

14.33 %

ROCE

16.51%

Profit Growth

358.02 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Natco Pharma Ltd.

Molnunat

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year32.99%
3 Year9.51%
5 Year2.37%

Profit Growth

1 Year358.02%
3 Year10.32%
5 Year-1.81%

ROE%

1 Year14.33%
3 Year8.51%
5 Year11.7%

ROCE %

1 Year16.51%
3 Year9.92%
5 Year13.7%

Debt/Equity

0.034

Price to Cash Flow

22.63

Interest Cover Ratio

90.6162790697674

CFO/PAT (5 Yr. Avg.)

0.963902482826741

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 49.71 0
Sep 2023 49.71 0
Jun 2023 49.76 0
Mar 2023 48.84 0
Dec 2022 48.82 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 229.1 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 90.6162790697674.
  • The Company has been maintaining an effective average operating margins of 27.7106183740992% in the last 5 years.
  • Company’s PEG ratio is 0.0409277674190536.
  • The company has an efficient Cash Conversion Cycle of 82.5617881747754 days.
  • Company has a healthy liquidity position with current ratio of 4.38435852372583.

 Limitations

  • The company has shown a poor revenue growth of 9.50903810745254% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 413 781.2 1048.3 930.5 625.3
Total Expenditure 345.5 453.5 544.6 488.2 387
Operating Profit 67.5 327.7 503.7 442.3 238.3
Other Income 18.6 17.5 14.6 24.7 29.5
Interest 3 1.2 3.2 3 3.8
Depreciation 38.1 37.6 39.9 40 40.4
Exceptional Items 0 0 0 0 0
Profit Before Tax 45 306.4 475.2 424 223.6
Tax 7.7 52.3 69.9 63.8 31.6
Profit After Tax 37.3 254.1 405.3 360.2 192
Adjusted EPS (Rs) 2.04 13.92 22.64 20.12 10.73

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1986.3 1790.2 1653.5 1767.8 2351
Total Expenditure 1169.8 1212.2 1238.3 1554.8 1530.2
Operating Profit 816.5 578 415.2 213 820.8
Other Income 129.8 123.8 103.5 94.6 109.4
Interest 18.8 20.6 11.3 13.3 8.6
Depreciation 80.1 98.1 115.2 138.4 150.9
Exceptional Items 0 0 0 0 0
Profit Before Tax 847.4 583.1 392.2 155.9 770.7
Tax 180.3 108.6 82.7 16.8 133.6
Net Profit 667.1 474.5 309.5 139.1 637.1
Adjusted EPS (Rs.) 36.55 26.07 16.96 7.62 34.91

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 36.5 36.4 36.5 36.5 36.5
Total Reserves 3526.7 3833.1 4054.6 4155.4 4665.5
Borrowings 0 0.9 0 0 0
Other N/C liabilities 83.1 116.6 142.9 134.9 116.9
Current liabilities 709.8 659.7 518.5 651.2 569
Total Liabilities 4356.1 4646.7 4752.5 4978 5387.9
Assets
Net Block 1214.9 1574.5 2005.9 2174.2 2233.8
Capital WIP 637.5 517.8 223.4 128.7 62.8
Intangible WIP 0 0 0 0 0
Investments 117.6 186.1 294.9 430.4 517.6
Loans & Advances 110.4 124.3 55.6 72.4 78.8
Other N/C Assets 8.3 4.1 4.2 4.6 0.2
Current Assets 2267.4 2239.9 2168.5 2167.7 2494.7
Total Assets 4356.1 4646.7 4752.5 4978 5387.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 847.4 583.1 392.2 155.9 770.7
Adjustment 12.1 45.2 58.4 118.5 85.4
Changes in Assets & Liabilities 14.2 -100.7 -190.2 -184.2 76.7
Tax Paid -174.9 -105.1 -76.9 -32.5 -148.4
Operating Cash Flow 698.8 422.5 183.5 57.7 784.4
Investing Cash Flow -645.2 -165 -3.2 -92.5 -436.6
Financing Cash Flow -52.2 -261.1 -183.1 35.6 -346.8
Net Cash Flow 1.4 -3.6 -2.8 0.8 1

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 48.82 48.84 49.76 49.71 49.71
devendranth alapati 0.01 0.01 0.01 0.01 0.01
durga devi nannapaneni 1.94 1.94 1.98 1.98 1.98
kantamani ratna kumar 0.05 0.05 0.06 0.06 0.06
natco aqua limited 0.01 0.01 0.01 0.01 0.01
natsoft information syste... 8.65 8.65 8.81 8.81 8.81
ndl infratech private lim... 0.05 0.05 0.05 0.05 0.05
neelima sita nannapaneni 0.10 0.10 0.10 0.10 0.10
rajeev nannapaneni 0.62 0.62 0.63 0.63 0.63
ramakrishna rao nannapane... 0.41 0.41 0.42 0.42 0.42
t anand babu 0.26 0.26 0.26 0.23 0.23
t anila 0.35 0.35 0.35 0.33 0.33
time cap pharma labs pri... - - - 9.59 9.59
tummala jansi 0.04 0.04 0.04 0.04 0.04
v c nannapaneni 12.38 12.39 15.66 15.66 15.66
venkata satya swathi kant... 8.76 8.76 8.92 8.92 8.92
vidyadhari tummala 0.24 0.24 0.25 0.25 0.25
vistra itcl india limited... - - - 2.28 2.28
vistra itcl india limited... - - - 0.33 0.33
time cap pharma labs priv... - - 9.59 - -
vistra itcl india limited... 0.33 0.33 0.33 - -
vistra itcl india limited... 2.24 2.24 2.28 - -
time cap pharma labs limi... 9.41 9.41 - - -
venkaiah chowdary nannapa... 2.98 2.98 - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 51.18 51.16 50.24 50.29 50.29
akash bhanshali - - 1.01 1.01 1.01
belgrave investment fund.... - - - - 1.88
investor education and pr... 0.46 0.46 0.47 0.47 0.47
life insurance corporatio... - - - 4.11 4.11
mirae asset midcap fund16... - - - - 2.66
tata mutual fund- tata eq... - - - - 1.00
icici prudential multicap... 4.08 - - 1.73 -
mirae asset healthcare fu... - 3.01 - 2.73 -
nomura singapore limited ... - 1.52 1.55 1.55 -
quant mutual fund - quant... - - - 1.05 -
tata mutual fund - tata s... - - - 1.00 -
icici prudential india op... - - 3.81 - -
life insurance corporatio... - - 4.11 - -
mirae asset emerging blue... 3.35 - 2.80 - -
quant mutual fund - quant... - - 1.01 - -
tata mutual fund- tata eq... - - 1.00 - -
icici prudential s&p bse ... - 4.30 - - -
life insurance corporatio... - 4.04 - - -
plenty private equity fii... 1.73 1.74 - - -
life insurance coporation... 4.04 - - - -
nomura singapore limited 1.69 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Natco Pharma informs about press release26 Feb 2024, 5:12PM Natco Pharma informs about disclosure23 Feb 2024, 2:31PM Natco Pharma informs about notice postal ballot22 Feb 2024, 3:11PM Natco Pharma - Quaterly Results14 Feb 2024, 2:08PM Natco Pharma - Quaterly Results14 Feb 2024, 2:08PM Natco Pharma - Quaterly Results14 Feb 2024, 2:08PM Natco Pharma invests around $2 million in Cellogen Therapeutics 17 Jan 2024, 5:35PM Natco Pharma submits analyst meet intimation25 Nov 2023, 11:51AM Natco Pharma informs about analyst meet 16 Nov 2023, 1:04PM Natco Pharma - Quaterly Results14 Nov 2023, 2:14PM Natco Pharma - Quaterly Results14 Nov 2023, 2:14PM Natco Pharma - Quaterly Results14 Nov 2023, 2:14PM Natco Pharma submits analyst meet intimation9 Nov 2023, 4:47PM Natco Pharma informs about book closure21 Sep 2023, 1:01PM NATCO Pharma informs about disclosure8 Sep 2023, 10:22AM NATCO Pharma informs about issuance of duplicate share certificate 7 Sep 2023, 2:37PM Natco Pharma informs about newspaper publication6 Sep 2023, 4:26PM Natco Pharma makes strategic investment in ISCA Inc31 Aug 2023, 10:23AM NATCO Pharma informs about issuance of duplicate share certificate 25 Aug 2023, 5:16PM Natco Pharma - Quaterly Results9 Aug 2023, 2:50PM Natco Pharma - Quaterly Results9 Aug 2023, 2:50PM Natco Pharma - Quaterly Results9 Aug 2023, 2:50PM Natco Pharma files ANDA for generic version of Erdafitinib Tablets26 Jul 2023, 2:50PM Natco Pharma gets EIR from USFDA for Andhra Pradesh manufacturing facility16 Jun 2023, 11:38AM Natco Pharma informs about disclosure 16 Jun 2023, 9:58AM Natco Pharma gets final nod for Tipiracil Hydrochloride and Tifluridine Tablets16 Jun 2023, 9:30AM Natco Pharma - Quaterly Results29 May 2023, 2:22PM Natco Pharma - Quaterly Results29 May 2023, 2:22PM Natco Pharma - Quaterly Results29 May 2023, 2:22PM Natco Pharma to incorporate subsidiary company in Indonesia20 Apr 2023, 12:13PM NATCO Pharma informs about closure of trading window1 Apr 2023, 2:28PM NATCO Pharma informs about issuance of duplicate share certificate 20 Mar 2023, 5:03PM Natco Pharma informs about buyback of equity shares 10 Mar 2023, 3:09PM NATCO Pharma informs about press release10 Mar 2023, 10:05AM Natco Pharma launches additional strengths for generic version of Revlimid in USA10 Mar 2023, 9:20AM NATCO Pharma informs about disclosure1 Mar 2023, 9:40AM Natco Pharma launches Pomalidomide Capsules in Canada1 Mar 2023, 9:23AM NATCO Pharma informs about issuance of duplicate share certificates27 Feb 2023, 11:46AM Natco Pharma files ANDA for generic version of Olaparib Tablets13 Feb 2023, 12:49PM Natco Pharma informs about disclosure13 Feb 2023, 11:01AM Natco Pharma - Quaterly Results9 Feb 2023, 2:00PM Natco Pharma - Quaterly Results9 Feb 2023, 2:00PM Natco Pharma - Quaterly Results9 Feb 2023, 2:00PM Natco Pharma informs about press release 4 Feb 2023, 3:53PM NATCO Pharma informs about earnings call4 Feb 2023, 11:33AM Natco Pharma informs about closure of trading window30 Dec 2022, 3:58PM Natco Pharma informs about disclosure5 Dec 2022, 12:21PM NATCO Pharma informs about issuance of duplicate share certificate3 Dec 2022, 12:27PM Natco Pharma - Quaterly Results22 Nov 2022, 4:26PM Natco Pharma - Quaterly Results22 Nov 2022, 4:26PM

Natco Pharma Stock Price Analysis and Quick Research Report. Is Natco Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Natco Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Natco Pharma cash from the operating activity was Rs 784.4 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Natco Pharma has a Debt to Equity ratio of 0.034 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Natco Pharma , the EPS growth was 358.017029874441 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Natco Pharma has OPM of 34.9128030625266 % which is a good sign for profitability.
     
  • ROE: Natco Pharma have a average ROE of 14.3321522973961 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Natco Pharma is Rs 990.55. One can use valuation calculators of ticker to know if Natco Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Natco Pharma

Natco Pharma Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page of Natco Pharma Ltd., where we provide a technical and comprehensive evaluation of the company's financial performance and growth potential. Our analysis is tailored for long-term stock investors, including doctors, who seek an in-depth understanding of the company's financial health. Our website offers pre-built screening tools, allowing investors to analyze specific parameters with ease. Annual reports and quarterly results are available as downloadable files on our website.

Natco Pharma Ltd Share Price

Track the share price trends of Natco Pharma Ltd. using our intuitive charts and real-time updates. Ticker platform provides historical data and analysis of the company's stock performance, enabling investors to make informed investment decisions.

Natco Pharma Ltd Balance Sheet

Evaluate the financial position of Natco Pharma Ltd. with our comprehensive balance sheet analysis. Utilize our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple approach, and DuPont Analysis, to calculate the company's fair value and growth potential accurately.

Natco Pharma Ltd Annual Report

Obtain the annual reports of Natco Pharma Ltd. from our website. These reports offer insights into the company's operational and financial performance, as well as strategic initiatives for the year. Ticker pre-built screening tools facilitate the filtering of reports based on specific parameters.

Natco Pharma Ltd Dividend

Stay updated on Natco Pharma Ltd.'s dividend payouts and dividend history with our user-friendly interface. Our website provides easy access to dividend-related information, allowing investors to review the company's past dividend payouts and consider them when making investment decisions.

Natco Pharma Ltd Quarterly Result

Access the quarterly results of Natco Pharma Ltd. through downloadable files available on our website. Ticker platform offers a comprehensive analysis of the company's financial performance, and our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, enhance the evaluation of the company's growth prospects.

Natco Pharma Ltd Stock Price

Keep track of Natco Pharma Ltd.'s stock price movements utilizing our user-friendly charts and real-time updates. Our platform offers in-depth analysis of the company's historical price trends, enabling investors to make informed investment decisions.

Natco Pharma Ltd Price Chart

Visualize the stock price movements of Natco Pharma Ltd. through our detailed price charts. Ticker platform provides insights into the company's historical performance, and our premium features, including fair value calculation using DCF Analysis, Earnings Multiple, and DuPont Analysis, offer investors greater clarity on the company's financial health.

Natco Pharma Ltd News

Stay updated with the latest news and developments of Natco Pharma Ltd. with our comprehensive news aggregation platform. Our reliable sources gather the most relevant news, enabling investors to make informed investment decisions.

Natco Pharma Ltd Concall Transcripts

Access the conference call transcripts of Natco Pharma Ltd. through downloadable files available on our website. These transcripts provide valuable insights into the company's management discussions, milestones, and financial performance. Utilize our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, to enhance the evaluation of the company's financial health.

Natco Pharma Ltd Investor Presentations

Explore the investor presentations of Natco Pharma Ltd. These presentations provide detailed overviews of the company's business operations, growth strategies, and financial performance. Our platform offers features to filter the presentations based on specific parameters, allowing users to identify relevant information for their investment decisions.

Natco Pharma Ltd Promoters

Get acquainted with the promoters of Natco Pharma Ltd., the individuals responsible for the company's growth and success. Ticker platform provides detailed information about the promoters, their backgrounds, and their contributions to the company's development.

Natco Pharma Ltd Shareholders

Understand the shareholders of Natco Pharma Ltd., including institutional investors and retail shareholders. The shareholder structure can provide valuable insights into the company's ownership patterns and potential market influence.

Read More
X